Literature DB >> 17513425

Management of phenylketonuria and hyperphenylalaninemia.

Hélène Ogier de Baulny1, Véronique Abadie, François Feillet, Loïc de Parscau.   

Abstract

Hyperphenylalaninemia (HPA) is the most frequently inherited disorder of amino acid metabolism (prevalence 1:10,000). In France, a nationwide neonatal screening was organized in 1978 to control its efficacy and patient follow-up. Phenylketonuria (PKU) was diagnosed in 81.6% of screened patients, the remaining affected with either non-PKU HPA (17.2%) or with cofactor deficiency (1.1%). French guidelines were established to specify the minimal diagnosis procedures and optimal treatment of patients. A low-phenylalanine diet must be started within the first days of life for all newborns whose blood phenylalanine levels are above 10 mg/dL (600 micromol/L). The dietary control must keep the phenylalanine levels between 2 and 5 mg/dL (120 and 300 micromol/L) until 10 y of age. Thereafter, a progressive and controlled relaxation of the diet is allowed, keeping levels below 15 mg/dL until the end of adolescence and below 20 mg/dL (1200 micromol/L) in adulthood. A lifelong follow-up is recommended for PKU women to prevent for maternal PKU.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17513425     DOI: 10.1093/jn/137.6.1561S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  18 in total

Review 1.  Sapropterin dihydrochloride for phenylketonuria.

Authors:  Usha Rani Somaraju; Marcus Merrin
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

2.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

3.  Breast-feeding success among infants with phenylketonuria.

Authors:  Sandra A Banta-Wright; Kathleen C Shelton; Nancy D Lowe; Kathleen A Knafl; Gail M Houck
Journal:  J Pediatr Nurs       Date:  2011-05-31       Impact factor: 2.145

4.  Hyperphenylalaninemia Correlated with Global Decrease of Antioxidant Genes Expression in White Blood Cells of Adult Patients with Phenylketonuria.

Authors:  Charlotte Veyrat-Durebex; Christelle Debeissat; Hélène Blasco; Franck Patin; Hélène Henique; Patrick Emond; Catherine Antar; Valérie Gissot; Olivier Herault; François Maillot
Journal:  JIMD Rep       Date:  2017-03-15

Review 5.  Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.

Authors:  Mark Sanford; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful.

Authors:  A M Das; K Goedecke; U Meyer; N Kanzelmeyer; S Koch; S Illsinger; T Lücke; H Hartmann; K Lange; H Lanfermann; L Hoy; X-Q Ding
Journal:  JIMD Rep       Date:  2013-11-13

7.  Incidence of neonatal hyperphenylalaninemia in fars province, South iran.

Authors:  Hamdollah Karamifar; Mahtab Ordoei; Zohreh Karamizadeh; Gholam Hossein Amirhakimi
Journal:  Iran J Pediatr       Date:  2010-06       Impact factor: 0.364

Review 8.  Proposed guidelines to evaluate scientific validity and evidence for genotype-based dietary advice.

Authors:  Keith A Grimaldi; Ben van Ommen; Jose M Ordovas; Laurence D Parnell; John C Mathers; Igor Bendik; Lorraine Brennan; Carlos Celis-Morales; Elisa Cirillo; Hannelore Daniel; Brenda de Kok; Ahmed El-Sohemy; Susan J Fairweather-Tait; Rosalind Fallaize; Michael Fenech; Lynnette R Ferguson; Eileen R Gibney; Mike Gibney; Ingrid M F Gjelstad; Jim Kaput; Anette S Karlsen; Silvia Kolossa; Julie Lovegrove; Anna L Macready; Cyril F M Marsaux; J Alfredo Martinez; Fermin Milagro; Santiago Navas-Carretero; Helen M Roche; Wim H M Saris; Iwona Traczyk; Henk van Kranen; Lars Verschuren; Fabio Virgili; Peter Weber; Jildau Bouwman
Journal:  Genes Nutr       Date:  2017-12-15       Impact factor: 5.523

9.  Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.

Authors:  Ania C Muntau; Alberto Burlina; François Eyskens; Peter Freisinger; Corinne De Laet; Vincenzo Leuzzi; Frank Rutsch; H Serap Sivri; Suresh Vijay; Milva Orquidea Bal; Gwendolyn Gramer; Renata Pazdírková; Maureen Cleary; Amelie S Lotz-Havla; Alain Munafo; Diane R Mould; Flavie Moreau-Stucker; Daniela Rogoff
Journal:  Orphanet J Rare Dis       Date:  2017-03-09       Impact factor: 4.123

10.  The proportion of tetrahydrobiopterin deficiency and PAH gene deficiency variants among cases with hyperphenyalaninemia in Western Iran.

Authors:  Keyvan Moradi; Reza Alibakhshi; Shohreh Khatami
Journal:  Indian J Hum Genet       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.